We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Use of PET/CT in Radiotherapy Planning for Head and Neck Cancer Provides Excellent Clinical Outcomes

By MedImaging staff writers
Posted on 31 Mar 2008
Using a combination of positron emission tomography (PET) and computed tomography (CT) for radiation therapy treatment planning in head and neck carcinoma patients provides for excellent, local, and regional disease control when compared to CT alone, according to a recent study.

CT has been the standard choice for staging and radiation therapy treatment planning for head and neck squamous cell carcinomas, which account for approximately 5% of malignancies worldwide; but PET has been shown to have advantages over CT and other imaging modalities in detecting primary tumors involving lymph nodes and distant metastatic disease not clearly otherwise identified. More...
PET alone does have several disadvantages, however, such as poor correlation to precise anatomic structures, but these negative impacts are significantly reduced when PET and CT are combined by fusing the separate scans taken on a hybrid scanner.

While it has been proven in several studies that PET/CT imaging is feasible for head and neck radiation therapy planning, very few studies have been done to determine the clinical outcomes. Therefore, researchers in the departments of radiation oncology, radiology, neoplastic and related disorders, and otolaryngology at the Medical College of Wisconsin (Milwaukee, USA) conducted this study to evaluate the clinical outcomes, including overall survival, disease-free survival, and the incidence of recurrence of patients receiving PET/CT-guided radiation therapy and the correlation of the clinical outcomes to the maximum standard uptake value obtained on the PET scan.

Between December 2002 and August 2006, 42 patients with a median age of 55, who were diagnosed with head and neck squamous cell carcinoma, were given PET/CT imaging as part of their radiation therapy planning. All patients were observed for at least six months following their treatment, with a mean follow-up time of 32 months.

Overall survival of the 42 study patients was 82.8% at two years and 74.1% at three years, superior to the survival rate that was found in a Radiation Therapy Oncology Group study in which patients received standard fractionation or accelerated fractionation with concomitant boost. That study was the largest randomized trial of radiation therapy in locally advanced head and neck cancer.

Disease-free survival for the 42 study patients was 71% and 66.9% at two and three years respectively. The cumulative incidence of recurrence was 18.7%. The study also found that standard uptake value is not a good predictor of local recurrence, and that dose escalation based on standard uptake value is unlikely to be a effective treatment strategy.

"PET/CT provides a higher level of confidence that we are not missing tumors as we attempt to lessen treatment side effects by delivering radiation therapy that tightly conforms in three dimensions to a given tumor volume,” said Christopher Schultz, M.D., professor of radiation oncology at the Medical College of Wisconsin. "Most importantly the PET/CT-guided conformal radiotherapy was clearly no worse, and based on our early results may in fact lead to superior clinical outcomes as compared to CT only planned radiotherapy.”

The study was published in the March 1, 2008, issue of the International Journal for Radiation Oncology*Biology*Physics.


Related Links:
Medical College of Wisconsin

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.